Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BRK0
UPID:
REEP2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BRK0; Q53EM8; Q9NYF2
Background:
Receptor expression-enhancing protein 2 plays a crucial role in endoplasmic reticulum network formation, shaping, and remodeling. It is also implicated in enhancing the cell surface expression of odorant receptors. This protein's involvement in cellular structure and function underscores its importance in biological systems.
Therapeutic significance:
Given its association with Spastic paraplegia 72, a neurodegenerative disorder marked by progressive weakness and spasticity of the lower limbs, understanding the role of Receptor expression-enhancing protein 2 could open doors to potential therapeutic strategies. Its precise function in disease pathology offers a promising avenue for targeted interventions.